Overcoming Resistance to AC0010, a Third Generation of EGFR Inhibitor, by Targeting c-MET and BCL-2

AC0010 is a pyrrolopyrimidine-based irreversible inhibitor of epidermal growth factor receptor (EGFR), structurally distinct from previously reported pyrimidine-based irreversible EGFR inhibitors such as osimertinib and rociletinib. AC0010 selectively inhibits EGFR T790M mutation in both preclinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Wanhong, Tang, Wei, Li, Tingting, Zhang, Xiaoying, Sun, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2018
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310688/
https://www.ncbi.nlm.nih.gov/pubmed/30504063
http://dx.doi.org/10.1016/j.neo.2018.11.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310688/
https://www.ncbi.nlm.nih.gov/pubmed/30504063
http://dx.doi.org/10.1016/j.neo.2018.11.004

Ejemplares similares